Jiangsu Aidea Pharmaceutical Group Co., Ltd. (SHA:688488)

SHA:688488 Revenue

Jiangsu Aidea Pharmaceutical Group had revenue of 184.15M CNY in the quarter ending September 30, 2026, a decrease of -3.03%. This brings the company's total for the last twelve months to 716.78M, up 6.77% year-over-year. In the year 2025, Jiangsu Aidea Pharmaceutical Group had annual revenue of 719.17M with 72.13% growth. That makes Jiangsu Aidea Pharmaceutical Group the 22,120th largest company in the world by revenue and 4,044th in China.

• Revenue (ttm): 716.78M
• Revenue Growth: +6.77%
• P/S Ratio: 7.04
• Revenue / Employee: 943.13K
• Employees: 760
• Market Cap: 4.99B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Manufacturing 660.33M 91.9%
• Biomedical Raw Materials 57.84M 8.1%

By Geography

Chart

• China 711.13M 99.0%
• Export 7.04M 1.0%

Fiscal year ended Dec 31, 2025 See the full SHA:688488 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	719.17M	301.37M	72.13%
Dec 31, 2024	417.80M	6.44M	1.57%
Dec 31, 2023	411.36M	167.14M	68.44%
Dec 31, 2022	244.22M	-11.49M	-4.49%
Dec 31, 2021	255.71M	-33.35M	-11.54%

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 5, 2026

Data Sources Report a data error